SCHEMBL6691200

SCHEMBL6691200

COc1ccc(-c2cc3ccccc3oc2=O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.74
HPGD P15428 2/20 0.74
RAB9A P51151 6/20 0.72
NPC1 O15118 5/20 0.72
GAA P10253 2/20 0.70
MAPT P10636 1/20 0.70
MAOB P27338 5/20 0.70
KDM4E B2RXH2 1/20 0.69
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
RXFP1 Q9HBX9 2/20 0.68
MIF P14174 1/20 0.68
SIRT3 Q9NTG7 1/20 0.68
ERAP1 Q9NZ08 1/20 0.68
CA1 P00915 1/20 0.68
CA2 P00918 1/20 0.68
NCOA1 Q15788 1/20 0.66
NCOA3 Q9Y6Q9 1/20 0.66
ESR1 P03372 1/20 0.66
GAPDH P04406 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7116819 0.86 NPC1 (0.83) ALDH1A1HPGDRAB9ANPC1GAA
SCHEMBL7124497 0.86 MAOB (0.86) RAB9ANPC1MAOBMEN1KMT2A
SCHEMBL22132859 0.85 MAOB (0.74) ALDH1A1HPGDRAB9ANPC1GAA
SCHEMBL4358139 0.84 NPC1 (1.00) ALDH1A1HPGDRAB9ANPC1GAA
SCHEMBL7123257 0.84 NPC1 (0.79) ALDH1A1HPGDRAB9ANPC1GAA
SCHEMBL14389070 0.83 MAOB (0.75) ALDH1A1HPGDRAB9ANPC1GAA
SCHEMBL17857190 0.82 MAOB (1.00) MAOBCA1CA2ADORA3XDH
SCHEMBL10453916 0.82 MAOB (0.80) RAB9ANPC1MAOBMEN1KMT2A
SCHEMBL177366 0.82 RAB9A (1.00) ALDH1A1HPGDRAB9ANPC1GAA
SCHEMBL30356319 0.82 RAB9A (1.00) ALDH1A1HPGDRAB9ANPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
EP-3354648-B1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF CHENGDU ZENITAR BIOMEDICAL TECH CO LTD (CN) 2022-04-06 EP disclosed
CN-108349959-B 4-substituted coumarin derivative and preparation method and application thereof 成都赜灵生物医药科技有限公司 2021-11-16 CN disclosed
WO-2020130120-A1 CANCER METASTASIS INHIBITOR 学校法人京都薬科大学 2020-06-25 WO disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 US disclosed
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2018-10-04 US disclosed
EP-3354648-A1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) 2018-08-01 EP disclosed
CN-108349959-A The coumarin derivative and its preparation method and application of 4 substitutions 贵州百灵企业集团制药股份有限公司 2018-07-31 CN disclosed
WO-2004089995-A2 PHOTOPOLYMERIZATION SYSTEMS AND THEIR USE ALBEMARLE CORPORATION (US) 2004-10-21 WO disclosed
US-20040198859-A1 Photopolymerization systems and their use NGUYEN CHAU K (US) 2004-10-07 US disclosed
US-6555523-B1 Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus CASCADE ESTATES LTD. (MU) 2003-04-29 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof MAP4, TUBA3C, ABCC1 ALDH1A1 725/4885HPGD 2933/4885RAB9A 3380/4885
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF MAP4, TUBA3C, ABCC1 ALDH1A1 725/4885HPGD 2933/4885RAB9A 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.